---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-24-000093"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2024-05-29T23:59:59+00:00"
generated_at: "2026-06-01T07:38:12.989919+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions approves 2.1M share increase to stock plan; reports NARCAN OTC launch, DoD contracts

## Summary
- Stockholders approved 2.1M share increase to stock incentive plan; full-value awards now count one-for-one.
- Elected directors DeGolyer, Fowler, White; say-on-pay passed; EY ratified as auditor.
- Launched OTC NARCAN Nasal Spray; FDA approved two-dose anthrax vaccine CYFENDUS.
- Won $379.6M DoD contract for RSDL kits and $235.8M contract for BioThrax.
- Cut ~$240M annualized OpEx; extended secured credit facility to May 2025; divested Travel Health up to $380M.

## SEC filing metadata
- accession: 0001367644-24-000093
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2024-05-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000093/0001367644-24-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000093/ebs-20240523.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-24-000093
- JSON: https://secwatch.observer/filing/0001367644-24-000093.json
- Plain text: https://secwatch.observer/filing/0001367644-24-000093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.